ValiRx launches self-testing products in East Midlands region
Personalised medicine firm ValiRx (LON:VAL) said this morning that it has struck a deal designed to expand sales in the UK’s East Midlands region of SELFCheck – a brand of personal health screening...
View ArticleValiRx gives upbeat update on VAL 101
AIM listed drug developer ValiRx (LON:VAL) this morning updated on the progress of VAL 101, a potential cancer treatment being developed in collaboration with London’s Imperial College. The pair are...
View ArticleValiRx inks biomarker deal
ValiRx (LON:VAL) said this morning it is acquiring the biomarkers arm of Finnish firm Pharmatest in a deal that values the business at £137,000. The AIM-listed drug developer is paying around £62,000...
View ArticleValiRx shares soar on skin cancer testing patent in Europe
ValiRx (LON:VAL) shares shot up around 35 per cent after the unexpected news that a newly acquired screening product for skin cancer had been granted a European patent. The test is for a biomarker,...
View ArticleValiRx shares soar on skin cancer testing patent in Europe
ValiRx (LON:VAL) shares shot up around 35 per cent after the unexpected news that a newly acquired screening product for skin cancer had been granted a European patent. The test is for a biomarker,...
View ArticleValiRx sets up scientific advisory board to support move to clinical trials
Life science firm ValiRx (LON:VAL) has established a scientific advisory board (SAB) to support the next steps in the development of its technologies and products in cancer therapeutics and...
View ArticleValiRx's VAL201 may have important role to play in prostate cancer treatment,...
ValiRx’s (LON:VAL) lead drug candidate may have an important role to play in the treatment of refractory prostate cancer. This was one of the conclusions of a review by independent experts carried in...
View ArticleValiRx collaboration points the way to clinical trials
ValiRx Plc (LON:VAL) has completed what it calls a material transfer agreement which will see the Institut Paoli & Calmettes in Marseille carry out translational and developmental studies on the...
View ArticleValiRx raises £900,000 to advance pipeline
Cancer and personalised medicine biotech ValiRx (LON:VAL) has raised £900,000 through a placing to fund ongoing pre-clinical work on its cancer treatments and pipeline projects. Six ValiRx directors,...
View ArticleValiRx full year revenues jump 157pct
ValiRx (LON:VAL) surged in morning trade after its full year report revealed a 157b percent jump in revenues and a significant increase in research and development (R&D) spending. ValiRx said it...
View ArticleValiRx wins new US patent for cancer screening gene biomarker
ValiRx (LON:VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, said it has been granted a patent in the US for a cancer screening method, using...
View ArticleValiRx reveals highly encouraging cancer study results
Drug developer ValiRx (LON:VAL) this morning released what can only be described as highly encouraging results from an independent late pre-clinical study on cancer compound VAL201. The data showed it...
View ArticleValiRx shares soar as reveals highly encouraging cancer study results
Shares in drug developer ValiRx (LON:VAL) soared 40 per cent today after encouraging results from an independent late pre-clinical study on its lead cancer compound VAL201. The data showed it...
View ArticleMellon looks at potential new medicines which could transform society - Pt 2
He built a reputation for being a being a savvy investor in emerging markets and mining, and in doing so amassed a personal fortune in excess of £500 million. Now Jim Mellon is turning his attention to...
View ArticleValiRx technology has potential for "wide range" of treatments
ValiRx (LON:VAL) said today it has made progress in all areas of the business after completing a two year international grant programme for its gene-silencing technology. ValiRx has been the leader...
View ArticleValiRx's lead compound has impact in breast cancer study
Drug developer ValiRx (LON:VAL) has had more good news from its lead compound VAL201, which has now shown well in a breast cancer study after encouraging prostate cancer data earlier. ValiRx said...
View ArticleValirX to raise £2.03 million to take VAL201 through first clinical trial
ValiRx (LON:VAL) is raising £2.03 million to take its VAL 201 candidate, targeting cancer, through its first clinical trial. The study aims to demonstrate that the compound is safe and show the...
View ArticleValiRx gears up for phase I clinical trials after £2 mln cash injection
Life sciences group ValiRx (LON:VAL) said the recent £2.03 mln cash call allows it to take VAL201 through first human clinical trials. It is hoped this potentially breakthrough treatment for cancer...
View ArticleValiRx appoints experienced medical monitoring officer for VAL201
Life sciences company ValiRx (LON:VAL) has unveiled Dr Alan Boyd as medical monitoring officer for the clinical development of VAL201. The company said the pharmaceutical physician will oversee the...
View ArticleValiRx appoints chief commercial officer
Drug developer and diagnostics specialist ValiRx (LON:VAL) has appointed a chief commercial officer. He is Samuel Ogunsalu, former head of commercialisation and the sector specialist for life...
View Article